Mitotech is a biotechnology company with a portfolio of novel small molecule drug candidates for the treatment of ophthalmic disorders. We have focussed on the clinical development of Visomitin – a highly efficient mitochondria-targeted antioxidant – in Phase 3 program for dry eye, and Phase 2 program in a number of other ophthalmic indications.

Our core team brings together cross-disciplinary scientific experts, seasoned clinical drug development professionals and experienced business leaders. Using this blend of business skills, industry expertise and fundamental scientific knowledge our company aims to tackle complex scientific problems, such as protection against mtROS and countering uncontrolled inflammation, and to turn the company’s innovative biology into pharmaceutical products. The company’s mission is to leverage the break-through in delivering highly active compounds into mitochondria across a wide spectrum of age-related and rare ophthalmic indications and to provide medicines based on this novel mechanism of action to patients worldwide.